chr9-130466723-A-G
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PVS1_ModeratePM2PP3_StrongPP5_Very_Strong
The NM_054012.4(ASS1):c.421-2A>G variant causes a splice acceptor change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000109 in 1,461,626 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_054012.4 splice_acceptor
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
ASS1 | NM_054012.4 | c.421-2A>G | splice_acceptor_variant | ENST00000352480.10 | |||
ASS1 | NM_000050.4 | c.421-2A>G | splice_acceptor_variant |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
ASS1 | ENST00000352480.10 | c.421-2A>G | splice_acceptor_variant | 1 | NM_054012.4 | P1 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD3 exomes AF: 0.0000119 AC: 3AN: 251174Hom.: 0 AF XY: 0.00000736 AC XY: 1AN XY: 135866
GnomAD4 exome AF: 0.0000109 AC: 16AN: 1461626Hom.: 0 Cov.: 31 AF XY: 0.0000124 AC XY: 9AN XY: 727138
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Citrullinemia type I Pathogenic:6Other:1
Pathogenic, criteria provided, single submitter | clinical testing | 3billion | Oct 02, 2021 | Canonical splice site: predicted to alter splicing and result in a loss or disruption of normal protein function through nonsense-mediated decay (NMD) or protein truncation. Multiple pathogenic variants are reported downstream of the variant (PVS1_VS). It is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.0000119, PM2). The variant has been reported multiple times as an established pathogenic variant (ClinVar ID: VCV000198386.5). Therefore, this variant is classified as pathogenic according to the recommendation of ACMG/AMP guideline. - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Aug 25, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Jan 10, 2024 | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Oct 01, 1995 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Feb 17, 2020 | Variant summary: ASS1 c.421-2A>G is located in a canonical splice-site and is predicted to affect mRNA splicing resulting in a significantly altered protein due to either exon skipping, shortening, or inclusion of intronic material. Several computational tools predict a significant impact on normal splicing: four predict the variant abolishes a 3' acceptor site. At least one publication reports experimental evidence demonstrating that this variant causes an in-frame skipping of exon 7 (Kobayashi_1994). The variant allele was found at a frequency of 1.2e-05 in 251174 control chromosomes, exclusively observed within the East Asian subpopulation (gnomAD). The variant, c.421-2A>G, is a common disease variant in Japan and Korea, and was reported in the literature in several homozygous and compound heterozygous individuals affected with Citrullinemia Type I (e.g. Kobayashi_1995, Lee_2013). These data indicate that the variant is very likely to be associated with disease. Publications also reported that the variant results in less than 2% of normal activity and the almost complete absence of the ASS1 protein in liver specimens of homozygous patients (Kobayashi_1995). Two clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation, and both of them classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
not provided, no classification provided | literature only | GeneReviews | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Nov 11, 2019 | NM_000050.4(ASS1):c.421-2A>G is classified as pathogenic in the context of type 1 citrullinemia. Sources cited for classification include the following: PMID 23246278. Classification of NM_000050.4(ASS1):c.421-2A>G is based on the following criteria: The variant is located at a canonical splice site, is expected to disrupt gene function and is reported in individuals with the relevant phenotype. Please note: this variant was assessed in the context of healthy population screening. - |
Citrullinemia Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 26, 2023 | This sequence change affects an acceptor splice site in intron 6 of the ASS1 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in ASS1 are known to be pathogenic (PMID: 18473344, 19006241). This variant is present in population databases (rs751930594, gnomAD 0.02%). Disruption of this splice site has been observed in individual(s) with citrullinemia (PMID: 7557970, 10987146). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. This variant is also known as IVS-6 -2 (a transition of A to G) or IVS6-2A>G. ClinVar contains an entry for this variant (Variation ID: 198386). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Jul 14, 2014 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at